Dimethylacetyl-β-cyclodextrin as a Novel Antagonist of Septic Shock Induced by Lipopolysaccharide and D-galactosamine in Mice

H. Arima, K. Motoyama, Y. Nishimoto, F. Hirayama, and K. Uekama

Kumamoto University

Purpose. To identify whether hydrophilic cyclodextrin derivatives (CyDs) improve septic shock induced by lipopolysaccharide (LPS)/D-galactosamine (D-gal) in mice.

Methods. Natural, methylated, sulfobutyl ether, hydroxyalkeyalted and branched CyDs were used. The effects of CyDs on nitric oxide (NO) and tumor necrosis factor- α (TNF- α) production in several mouse macrophages stimulated with LPS in vitro were investigated. Nitrite, iNOS and TNF- α were determined by Griess method, Western blotting and ELISA, respectively. The mRNA of *iNOS* and *TNF-\alpha* were determined by RT-PCR analysis. The interaction of LPS with CyDs was evaluated by utilizing a competitive inclusion phenomenon. The binding of FITC-labeled LPS to the surface of RAW264.7 cells and the expression of CD14 and Toll-like receptor 4 (TLR4)/MD2 complex were measured by a flow cytometry. The effects of CyDs on septic shock were evaluated by the survival rate of mice after intraperitoneal injection of saline containing LPS/D-gal in the absence and presence of CyDs.

Results. Of 15 CyDs, dimethyl- α -CyD (DM- α -CyD) and dimethylacetyl- β -CyD (DMA- β -CyD) have greater inhibitory activity than do the other CyDs against NO production in mouse macrophages stimulated with LPS. Likewise, DM- α -CyD and DMA- β -CyD impaired the TNF- α production in the macrophages. DMA- β -CyD, but not DM- α -CyD, had a greater interaction with LPS. On the contrary, DM- α -CyD, not DMA- β -CyD, released CD14 from lipid rafts of RAW264.7 cell membranes into the medium, although no CyDs affected the level of TLR4/MD2 complex on the membranes. DMA- β -CyD, not DM- α -CyD, markedly improved a survival rate of septic mice treated with LPS/D-gal, reflecting the attenuation of the plasma TNF- α level after co-administration of DMA- β -CyD.

Conclusions. These results suggest the potential use of DMA-β-CyD as an antagonist of septic shock induced by LPS.

Arima et al. Pharm. Res., 18, 1167-1173 (2001).